Skin-structure infections

Also known as: Skin Infection / Skin Infections / Minor skin infection / Perleche / Skin infection NOS / Skin Diseases, Infectious

DrugDrug NameDrug Description
DB00355AztreonamA monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
DB00537CiprofloxacinCiprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
DB00254DoxycyclineDoxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline [FDA label]. This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines [A174034]. Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing.
DB00303ErtapenemErtapenem is a carbapenem antibiotic drug that is marketed under the trade name Invanz by Merck & Co. pharmaceutical company. It is structurally similar to [meropenem] and possess a 1-beta-methyl group.
DB14112Human vaccinia virus immune globulinHuman vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of anti-vaccinia virus antibody [FDA Label, A33814]. The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. Most compounds used currently are intravenous formulations, which contain no preservatives - unlike prior intramuscular compounds which contained thiomersal, a mercury derivative preservative that could be potentially teratogenic [A33814]. Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with its availability and effectiveness [A33798, A33814].
DB00218MoxifloxacinMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
DB06812Povidone-iodinePovidone-iodine is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. During in vitro testing to demonstrate anti-bacterial activity it was found that the complex was less toxic in mice than tincture of iodine. Human clinical trials showed the product to be superior to other iodine formulations. Povidone-iodine was immediately marketed, and has since become the universally preferred iodine antiseptic.
DB13503TyrothricinTyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus [A36353]. This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years of therapeutic use the complex has provided [A36360]. Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do exist [L4028].
DrugDrug NameTargetType
DB00355AztreonamPenicillin-binding protein 3target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 2-alphatarget
DB00537CiprofloxacinCytochrome P450 1A2enzyme
DB00537CiprofloxacinCytochrome P450 3A4enzyme
DB00537CiprofloxacinCytochrome P450 3A5enzyme
DB00537CiprofloxacinCytochrome P450 3A7enzyme
DB00537CiprofloxacinMultidrug resistance protein 1transporter
DB00537CiprofloxacinPotassium voltage-gated channel subfamily H member 2target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Btarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug resistance protein MdtKtarget
DB00537CiprofloxacinGyrase Atarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug and toxin extrusion protein 1transporter
DB00537CiprofloxacinMultidrug and toxin extrusion protein 2transporter
DB00537CiprofloxacinSerum albumincarrier
DB00254Doxycycline16S rRNAtarget
DB00254DoxycyclineSolute carrier family 22 member 6transporter
DB00254DoxycyclineCytochrome P450 3A4enzyme
DB00254DoxycyclineATP-binding cassette sub-family B member 5transporter
DB00303ErtapenemPenicillin-binding protein 2target
DB00303ErtapenemPeptidoglycan synthase FtsItarget
DB00303ErtapenemPenicillin-binding protein 1Atarget
DB00303ErtapenemD-alanyl-D-alanine carboxypeptidase DacCtarget
DB00303ErtapenemD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00303ErtapenemPenicillin-binding protein 1Btarget
DB00303ErtapenemPeptidoglycan synthase FtsItarget
DB00303ErtapenemPenicillin-binding protein 2target
DB00218MoxifloxacinDNA gyrase subunit Atarget
DB00218MoxifloxacinDNA topoisomerase 4 subunit Atarget
DB00218MoxifloxacinDNA topoisomerase 2-alphatarget
DB00218MoxifloxacinCytochrome P450 1A2enzyme
DB13503TyrothricinPhospholipid membranetarget
DrugDrug NamePhaseStatusCount
DB04272Citric Acid2Not Yet Recruiting1
DB00254Doxycycline2Not Yet Recruiting1
DB09154Sodium Citrate2Not Yet Recruiting1
DB01015Sulfamethoxazole2Not Yet Recruiting1
DB00440Trimethoprim2Not Yet Recruiting1